| Aug 12 |
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
|
| Jul 1 |
Invivyd announces its addition to Russell 2000 and Russell 3000 Indexes
|
| Jul 1 |
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
|
| Jun 27 |
Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future
|
| Jun 14 |
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
|
| Jun 3 |
Invivyd to Participate at the Jefferies Global Healthcare Conference
|
| May 31 |
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Ser...
|
| May 31 |
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
|
| May 29 |
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
|
